N-Desmethylapalutamide
N-Desmethylapalutamide is a nonsteroidal antiandrogen (NSAA) that is a major active metabolite of the drug apalutamide. It is used in the treatment of prostate cancer. N-Desmethylapalutamide is formed in the body through the metabolism of apalutamide by the cytochrome P450 enzyme CYP2C8.
Pharmacology[edit]
N-Desmethylapalutamide acts as an androgen receptor (AR) antagonist. It binds to the AR and inhibits the action of androgens, which are male sex hormones such as testosterone and dihydrotestosterone (DHT). This inhibition prevents the growth of prostate cancer cells that rely on androgens for proliferation.
Metabolism[edit]
The conversion of apalutamide to N-Desmethylapalutamide is primarily mediated by the enzyme CYP2C8. This metabolic pathway is significant because N-Desmethylapalutamide retains similar pharmacological activity to its parent compound, apalutamide, contributing to the overall therapeutic effects.
Clinical Significance[edit]
N-Desmethylapalutamide, as an active metabolite, plays a crucial role in the efficacy of apalutamide in treating prostate cancer. Understanding its pharmacokinetics and pharmacodynamics is important for optimizing treatment regimens and managing potential drug interactions.
See also[edit]
References[edit]
External links[edit]
 | This medical article is a stub. You can help WikiMD by expanding the page. |
